Ticagrelor
Small molecule targets P2RY12 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | BRILINTA | — | 2015-09-03 – 2024-03-22 | fda.gov ↗ |
| Approved | US (FDA) | BRILINTA | — | 2011-07-20 | fda.gov ↗ |
| Approved | EU (EMA) | Brilique | — | 2010-12-03 | europa.eu ↗ |
Trials 300 · started per year
Also used as a comparator or background therapy in 140 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05278637 Comparator | Nov 2013 → Dec 2016 | aspirin resistance, nuclear ribonucleic acid, platelet aggregation, spontaneous | Duke University | Completed | No outcome recorded |
| Phase 18 trials | ||||||
| Phase 1 | NCT05373277 Comparator | May → Dec 2022 | — | Helsinki University Central Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT04091074 Comparator | Jan → Dec 2022 | carotid stenosis | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT05162131 Background | Dec 2021 → Dec 2022 | — | SFJ Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT04945616 Background | Jul → Oct 2021 | thrombotic disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03671941 Comparator | May → Jun 2018 | acute coronary syndrome | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT03492385 Background | Apr → Sep 2018 | — | SFJ Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03441412 Background | Feb → Mar 2018 | — | Vastra Gotaland Region | Completed | No outcome recorded |
| Phase 1 | NCT01526577 Comparator | Mar → Nov 2012 | acute coronary syndrome | LG Life Sciences | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03533153 Background | Mar 2021 → Dec 2023 | myocardial infarction | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
| Phase 1/2 | NCT02335099 Comparator | Dec 2014 → Jun 2019 | end stage renal failure | University of Virginia | Completed | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT04122170 Comparator | Sep 2019 → Sep 2021 | — | SFJ Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03039205 Comparator | Nov 2017 → Dec 2019 | coronary artery disorder, impaired renal function disease, platelet aggregation, spontaneous | University of Sao Paulo | Completed | No outcome recorded |
| Phase 2 | NCT02925923 Comparator | Nov 2016 → Jan 2018 | acute coronary syndrome, intermediate coronary syndrome | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT02507323 Comparator | Feb 2016 → Aug 2017 | cardiovascular disorder | Yochai Birnbaum | Withdrawn | No outcome recorded |
| Phase 2 | NCT02293395 Background | Apr 2015 → Oct 2016 | acute coronary syndrome | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02070653 Comparator | Mar 2014 → Jul 2016 | abdominal aortic aneurysm | Uppsala University | Completed | No outcome recorded |
| Phase 2 | NCT01919723 Comparator | Feb 2014 → Dec 2015 | acute coronary syndrome | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT01898442 Comparator | Sep 2013 → Jun 2014 | coronary artery disorder | University of Florida | Completed | No outcome recorded |
| Phase 2 | NCT02120092 Comparator | Oct 2010 → Dec 2013 | acute coronary syndrome | Medical University of Vienna | Completed | No outcome recorded |
| Phase 325 trials | ||||||
| Phase 3 | NCT07257198 Comparator | Mar 2026 → Jan 2030 expected | ST-elevation myocardial infarction | Montreal Heart Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT07476898 Comparator | Mar 2026 → Jul 2028 expected | stroke disorder | First Hospital of China Medical University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06591338 Comparator | Sep 2024 → Sep 2025 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT06561867 Comparator | Aug 2024 → Nov 2025 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT06591377 Comparator | Aug 2024 → Sep 2025 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT06202755 Comparator | Mar 2024 → Jun 2025 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT06196047 Comparator | Dec 2023 → Dec 2024 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT05553613 Comparator | Oct 2022 → Oct 2023 | ischemic stroke | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 3 | NCT06591312 Comparator | May 2022 → Sep 2024 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT06591390 Comparator | Feb 2022 → Sep 2024 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT04718025 Comparator | Feb 2022 → Jun 2024 | ST-elevation myocardial infarction, intermediate coronary syndrome | Collegium Medicum w Bydgoszczy | Unknown | No outcome recorded |
| Phase 3 | NCT05077683 Background | Oct 2021 → Mar 2023 | acute myocardial infarction, thrombotic disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT06120725 Comparator | Sep 2021 → Sep 2023 | ischemic stroke | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 3 | NCT04754789 Background | Feb → Mar 2021 | ST-elevation myocardial infarction | Assiut University | Unknown | No outcome recorded |
| Phase 3 | NCT04045665 Background | Dec 2019 → Aug 2026 overdue | atrial fibrillation, hemorrhagic disease, stroke disorder | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 3 | NCT03884530 Comparator | May 2019 → Sep 2020 | ischemic stroke | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 3 | NCT02866175 Background | Feb 2017 → Jun 2019 | atrial fibrillation | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Completed | No outcome recorded |
| Phase 3 | NCT02989558 Comparator | Dec 2016 → Feb 2020 | aortic valve stenosis | University of Athens | Completed | No outcome recorded |
| Phase 3 | NCT02429271 Comparator | Aug 2015 → Feb 2019 | ST-elevation myocardial infarction | Hellenic Cardiovascular Research Society | Completed | No outcome recorded |
| Phase 3 | NCT02298088 Comparator | Aug 2015 → Dec 2017 | ST-elevation myocardial infarction | Hospital do Coracao | Completed | No outcome recorded |
| Phase 3 | NCT02325466 Comparator | Apr 2015 → May 2018 | peripheral arterial disease, type 2 diabetes mellitus | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 3 | NCT02164864 Background | Jul 2014 → Jun 2017 | atrial fibrillation | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT01961856 Comparator | Sep 2013 → Feb 2014 | — | University of Patras | Completed | No outcome recorded |
| Phase 3 | NCT01830543 Background | May 2013 → Jul 2016 | atrial fibrillation | Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01531114 Comparator | May 2013 → Jul 2015 | ST-elevation myocardial infarction | Gennaro Sardella | Completed | No outcome recorded |
| Phase 476 trials | ||||||
| Phase 4 | NCT07684742 Comparator | Jul 2026 → Jul 2031 expected | ST-elevation myocardial infarction, acute coronary syndrome, intermediate coronary syndrome | Gyeongsang National University Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07195812 Comparator | Oct 2025 → May 2028 expected | ST-elevation myocardial infarction | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06763744 Comparator | Jun 2025 → Jul 2029 expected | acute coronary syndrome, bleeding disorder, vascular-type | Samsung Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06451198 Background | May 2025 → Dec 2028 expected | coronary artery disorder | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06691191 Comparator | Jan 2025 → Aug 2026 overdue | coronary artery disorder | University of Florida | Recruiting | No outcome recorded |
| Phase 4 | NCT06756945 Background | Jan 2025 → Dec 2026 expected | ST-elevation myocardial infarction | Beijing Anzhen Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06013020 Background | Apr 2024 → Dec 2026 expected | ST-elevation myocardial infarction | Zunyi Medical College | Recruiting | No outcome recorded |
| Phase 4 | NCT05782270 Background | Apr 2023 → Sep 2025 overdue | coronary artery disorder | China National Center for Cardiovascular Diseases | Recruiting | No outcome recorded |
| Phase 4 | NCT04937699 Comparator | Mar 2023 → Dec 2026 expected | acute coronary syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 4 | NCT05767723 Comparator | Feb 2023 → May 2025 overdue | acute coronary syndrome | Hospital Israelita Albert Einstein | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05183178 Comparator | Feb 2022 → Aug 2025 | acute coronary syndrome | Vastra Gotaland Region | Completed | No outcome recorded |
| Phase 4 | NCT05116995 Comparator | Nov 2021 → Nov 2023 | myocardial infarction, thrombotic disease | Nova Scotia Health Authority | Unknown | No outcome recorded |
| Phase 4 | NCT04240834 Background | Feb 2021 → Dec 2025 overdue | acute coronary syndrome | Fu Wai Hospital, Beijing, China | Recruiting | No outcome recorded |
| Phase 4 | NCT04331145 Comparator | Jun 2020 → Feb 2021 | aortic valve stenosis | Andres Iñiguez Romo | Completed | No outcome recorded |
| Phase 4 | NCT04442919 Comparator | Jun 2020 → Jan 2024 | intermediate coronary syndrome | Collegium Medicum w Bydgoszczy | Completed | No outcome recorded |
| Phase 4 | NCT04255602 Comparator | Feb 2020 → Dec 2024 | acute coronary syndrome, coronary artery disorder | Shanghai Tong Ren Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04734353 Comparator | Jan 2020 → Jun 2021 | coronary artery disorder | Gyeongsang National University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04006288 Comparator | Sep 2019 → Jan 2022 | coronary artery disorder | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT03869268 Comparator | Apr 2019 → Dec 2021 | acute coronary syndrome | Sheffield Teaching Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT03008083 Comparator | Jan 2019 → Dec 2020 | — | Shanghai MicroPort Medical (Group) Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT03775746 Comparator | Jan 2019 → Dec 2021 | acute coronary syndrome | East and North Hertfordshire NHS Trust | Unknown | No outcome recorded |
| Phase 4 | NCT03708588 Comparator | Sep 2018 → Dec 2020 | — | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT03182855 Comparator | Sep 2018 → Jun 2019 | ST-elevation myocardial infarction, acute coronary syndrome | University of Aarhus | Unknown | No outcome recorded |
| Phase 4 | NCT03620760 Comparator | Aug 2018 → Dec 2020 | coronary stenosis, intermediate coronary syndrome | Xiaofan Wu | Unknown | No outcome recorded |
| Phase 4 | NCT03551964 Comparator | Aug 2018 → Feb 2024 | acute myocardial infarction, cardiogenic shock | Faculty Hospital Kralovske Vinohrady | Completed | No outcome recorded |
| Phase 4 | NCT03489863 Comparator | May 2018 → Mar 2019 | coronary artery disorder | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT02931045 Comparator | Dec 2017 → Dec 2018 | myocardial infarction | Medical University of Warsaw | Completed | No outcome recorded |
| Phase 4 | NCT03273075 Comparator | Sep 2017 → May 2021 | acute coronary syndrome, cardiac arrest | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 4 | NCT03027934 Comparator | Aug → Oct 2017 | diabetes mellitus | CirQuest Labs, LLC | Withdrawn | No outcome recorded |
| Phase 4 | NCT02943369 Background | Jul → Nov 2017 | ST-elevation myocardial infarction | Attikon Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03119012 Comparator | Apr → Dec 2017 | atherosclerosis, coronary artery disorder | Samsung Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT03150667 Comparator | Apr 2017 → Apr 2019 | acute coronary syndrome, chronic kidney disease | North Texas Veterans Healthcare System | Unknown | No outcome recorded |
| Phase 4 | NCT05247385 Comparator | Mar 2017 → Feb 2021 | coronary artery disorder | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT03881943 Comparator | Jan 2017 → Dec 2018 | acute coronary syndrome | The University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT02874092 Comparator | Nov 2016 → Apr 2019 | rheumatoid arthritis | NYU Langone Health | Completed | No outcome recorded |
| Phase 4 | NCT02939248 Comparator | Oct 2016 → Dec 2018 | intermediate coronary syndrome | Collegium Medicum w Bydgoszczy | Completed | No outcome recorded |
| Phase 4 | NCT02733341 Comparator | Jul 2016 → Oct 2018 | ST-elevation myocardial infarction, acute coronary syndrome, vascular occlusion disorder | The Royal Wolverhampton Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 4 | NCT02939235 Comparator | Jul 2016 → Dec 2017 | intermediate coronary syndrome | Collegium Medicum w Bydgoszczy | Completed | No outcome recorded |
| Phase 4 | NCT02545933 Background | Feb 2016 → May 2019 | myocardial infarction | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT02587260 Comparator | Dec 2015 → Feb 2017 | cardiovascular disorder | Erasmus Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT04369534 Comparator | Dec 2015 → Nov 2019 | ST-elevation myocardial infarction, acute coronary syndrome, platelet aggregation, spontaneous | University of Zagreb | Completed | No outcome recorded |
| Phase 4 | NCT02626169 Comparator | Dec 2015 → Jan 2018 | atherosclerosis | Baylor College of Medicine | Withdrawn | No outcome recorded |
| Phase 4 | NCT02580149 Comparator | Oct 2015 → Mar 2016 | ischemic disease | Michael Wolzt, Prof. MD | Completed | No outcome recorded |
| Phase 4 | NCT02767401 Comparator | Sep 2015 → Aug 2018 | arterial occlusion, myocardial stunning | The First Affiliated Hospital of Dalian Medical University | Completed | No outcome recorded |
| Phase 4 | NCT02612116 Comparator | Sep 2015 → Aug 2016 | intermediate coronary syndrome | Collegium Medicum w Bydgoszczy | Completed | No outcome recorded |
| Phase 4 | NCT02627521 Background | Jul 2015 → Aug 2017 | coronary artery disorder | Unity Health Toronto | Unknown | No outcome recorded |
| Phase 4 | NCT02270242 Comparator | Jul 2015 → Jul 2019 | cardiovascular disorder | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 4 | NCT02487732 Comparator | Jul 2015 → Aug 2016 | acute coronary syndrome | Korea University Anam Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02428374 Comparator | May 2015 → Apr 2018 | — | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT02658838 Background | Apr 2015 → Aug 2016 | — | Beijing Anzhen Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02287909 Comparator | Dec 2014 → Oct 2017 | coronary artery disorder | University of Florida | Completed | No outcome recorded |
| Phase 4 | NCT02284048 Comparator | Nov 2014 → Nov 2016 | coronary microvascular disorder | Second Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 4 | NCT02206815 Comparator | Sep 2014 → Feb 2019 | atrial fibrillation, coronary artery disorder | Genshan Ma | Completed | No outcome recorded |
| Phase 4 | NCT02053909 Comparator | Sep 2014 → Aug 2020 | vein disorder | Boca Raton Regional Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02217878 Comparator | Aug 2014 → Jun 2015 | ST-elevation myocardial infarction | Collegium Medicum w Bydgoszczy | Completed | No outcome recorded |
| Phase 4 | NCT02118870 Comparator | Jun 2014 → Sep 2017 | acute coronary syndrome | Diagram B.V. | Completed | No outcome recorded |
| Phase 4 | NCT02018055 Comparator | Feb 2014 → Jan 2021 | acute myocardial infarction | The Catholic University of Korea | Completed | No outcome recorded |
| Phase 4 | NCT02032290 Comparator | Feb → Dec 2014 | ST-elevation myocardial infarction, acute coronary syndrome, intermediate coronary syndrome | Azienda Policlinico Umberto I | Unknown | No outcome recorded |
| Phase 4 | NCT01916902 Comparator | Feb 2014 → Feb 2015 | acute coronary syndrome, coronary artery disorder | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT02032303 Comparator | Feb → Dec 2014 | ST-elevation myocardial infarction, acute coronary syndrome, intermediate coronary syndrome | Azienda Policlinico Umberto I | Unknown | No outcome recorded |
| Phase 4 | NCT01869309 Comparator | Jan 2014 → Dec 2015 | coronary artery disorder | LifeBridge Health | Unknown | No outcome recorded |
| Phase 4 | NCT02046486 Comparator | Jan 2014 → Jan 2015 | ST-elevation myocardial infarction | University of Patras | Completed | No outcome recorded |
| Phase 4 | NCT02215993 Comparator | Jul 2013 → Sep 2014 | acute coronary syndrome, blood platelet disease | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 4 | NCT02317198 Comparator | Jun 2013 → Nov 2018 | acute coronary syndrome, intermediate coronary syndrome, myocardial infarction | St. Antonius Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01996735 Comparator | Apr → Nov 2013 | — | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02402491 Comparator | Jan 2013 → Jun 2015 | — | Beijing Anzhen Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01805570 Comparator | Nov 2012 → Mar 2013 | myocardial infarction | David Antoniucci | Completed | No outcome recorded |
| Phase 4 | NCT02071966 Comparator | Nov 2012 → Dec 2015 | acute coronary syndrome | Catholic University of the Sacred Heart | Terminated | No outcome recorded |
| Phase 4 | NCT01812200 Comparator | Oct 2012 → May 2013 | acute coronary syndrome, atrial fibrillation | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT01700322 Comparator | Aug 2012 → Jul 2016 | coronary artery disorder | Johannes Gutenberg University Mainz | Completed | No outcome recorded |
| Phase 4 | NCT01589978 Background | May 2012 → Aug 2014 | coronary artery disorder | Boston Scientific Corporation | Completed | No outcome recorded |
| Phase 4 | NCT01575795 Comparator | Apr 2012 → Feb 2013 | ST-elevation myocardial infarction | University of Patras | Completed | No outcome recorded |
| Phase 4 | NCT01587651 Comparator | Mar 2012 → Feb 2013 | coronary artery disorder | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT01510171 Comparator | Jan → Jun 2012 | ST-elevation myocardial infarction | Careggi Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01456364 Comparator | Sep 2011 → Apr 2014 | coronary artery disorder | German Heart Center Munich | Unknown | No outcome recorded |
| Phase 4 | NCT01373411 Comparator | Sep 2011 → Mar 2015 | coronary artery disorder | Cardiology Research UBC | Completed | No outcome recorded |
| Phase not applicable19 trials | ||||||
| — | NCT06981390 Comparator | May 2026 → Feb 2027 expected | coronary artery disorder | Kexiang Liu, MD | Not yet recruiting | No outcome recorded |
| — | NCT07495969 Background | Apr 2026 → Dec 2027 expected | cerebral artery occlusion, ischemic stroke | Feng Gao | Not yet recruiting | No outcome recorded |
| — | NCT06943586 Comparator | Apr 2025 → Apr 2028 expected | transient ischemic attack | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| — | NCT05980195 Background | Jul 2024 → Dec 2025 overdue | carotid stenosis, cognitive impairment with or without cerebellar ataxia | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT05885932 Comparator | Aug 2023 → Sep 2025 overdue | ischemic stroke, precerebral artery stenosis | Xuanwu Hospital, Beijing | Recruiting | No outcome recorded |
| — | NCT05858918 Comparator | Oct 2022 → Mar 2023 | intermediate coronary syndrome | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| — | NCT05209412 Background | Feb 2022 → Feb 2024 | coronary stenosis | Xijing Hospital | Unknown | No outcome recorded |
| — | NCT04995159 Background | Sep 2021 → Jan 2026 overdue | coronary artery disorder | Lepu Medical Technology (Beijing) Co., Ltd. | Not yet recruiting | No outcome recorded |
| — | NCT04744571 Background | Feb 2021 → Dec 2022 | arterial occlusion, coronary artery disorder | Beijing Anzhen Hospital | Unknown | No outcome recorded |
| — | NCT03971500 Background | Aug 2019 → Oct 2023 overdue | coronary artery disorder | Nanjing First Hospital, Nanjing Medical University | Active not recruiting | No outcome recorded |
| — | NCT04012541 Background | Jul 2019 → Mar 2021 | acute myocardial infarction, tooth disorder | Seoul National University Bundang Hospital | Unknown | No outcome recorded |
| — | NCT03797651 Background | Apr 2019 → Apr 2025 | acute coronary syndrome | Yonsei University | Unknown | No outcome recorded |
| — | NCT03447379 Background | Dec 2017 → Mar 2022 | coronary artery disorder | Gangnam Severance Hospital | Completed | No outcome recorded |
| — | NCT03435133 Comparator | Nov 2015 → Oct 2018 | ST-elevation myocardial infarction | AORTICA Group | Completed | No outcome recorded |
| — | NCT02303717 Background | Dec 2014 → Dec 2017 | coronary artery disorder | NHS National Waiting Times Centre Board | Unknown | No outcome recorded |
| — | NCT02081443 Comparator | Apr 2014 → Oct 2015 | coronary artery disorder | University of Florida | Completed | No outcome recorded |
| — | NCT02699008 Comparator | Jan 2014 → Aug 2015 | acute coronary syndrome | Wuhan Asia Heart Hospital | Completed | No outcome recorded |
| — | NCT01852214 Comparator | Feb 2013 → Jul 2015 | coronary artery disorder, type 2 diabetes mellitus | University of Florida | Completed | No outcome recorded |
| — | NCT01852175 Comparator | Jan 2012 → Jun 2014 | coronary artery disorder | University of Florida | Completed | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 445 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ticagrelor | “patients aged 18 years or older with an acute coronary syndrome who completed the IVUS-ACS study and who had no major ischaemic or bleeding events after 1-month treatment with...” PMID 38599220 ↗ Apr 2024431“Randomization will be stratified by stent type (cobalt-chromium everolimus-eluting stents, platinum-chromium everolimus-eluting stents, and sirolimus-eluting stents with...” PMID 29447787 ↗ Dec 2017 “Every antiplatelet-naïve patient undergoing an elective procedure will be given 300 mg aspirin and loading dose of one of P2Y12 receptor inhibitors (e.g., 600 mg clopidogrel,...” NCT02601157 ↗ “Participants were randomly assigned (1:1) to receive DAPT (ticagrelor 90 mg twice daily plus aspirin 100 mg once daily) for 12 months or the same dual antiplatelet regimen for...” PMID 42120081 ↗ May 2026 “De-escalation strategy indicates conventional DAPT (ticagrelor 90 mg twice daily + aspirin 100 mg once daily) for 1 month, followed by de-escalation DAPT (ticagrelor 60 mg...” NCT04755387 ↗ “The study will be sufficiently powered to provide data primarily regarding the safety of dual therapy with rivaroxaban and ticagrelor over the traditional triple therapy in...” PMID 26003433 ↗ May 2015 “* Ticagrelor: Per treating physician, peri-procedural loading dose (180 mg), subsequent maintenance dose (90 mg 2x daily); maintenance aspirin doses \>100 mg may reduce...” NCT01589978 ↗ “Aggressive medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per...” NCT04948749 ↗ “Patients randomized to the antithrombotic monotherapy treatment receive any of the commercially available oral P2Y12 inhibitors (clopidogrel, ticagrelor, prasugrel) and...” NCT05955365 ↗ “Standard medical treatment consists of dual antiplatelet treatment (aspirin 100 mg per day for the entire follow-up, clopidogrel 75 per day mg, or ticagrelor 90 mg twice per...” NCT05980195 ↗ “Dual antiplatelet therapy with aspirin and either clopidogrel, prasugrel or ticagrelor will be recommended for 12 months duration in the Xience stent arm but only 4 months...” NCT02303717 ↗ “It consists in oral ingestion of 1.5g of paracetamol (Contents of 3 Doliprane® capsules 500 mg) and 60 mg prasugrel (6 tablets Efient ® 10 mg) or 180 mg ticagrelor ( 2 tablets...” NCT02251249 ↗ “Unlike prasugrel and ticagrelor, which are potent P2Y12 inhibitors, clopidogrel is activated in the liver via the cytochrome P450 2C19 (CYP2C19) metabolic pathway to exert its...” NCT06763744 ↗ “Aspirin in combination with a P2Y12 receptor antagonist (either clopidogrel or ticagrelor will be selected by investigators according to the degree of ischemia) in the first...” NCT04995159 ↗ “Normal, rapid, or ultrarapid CYP2C19 metabolizers continued clopidogrel monotherapy for 90 days whereas loss-of-function allele carriers switched to prasugrel or ticagrelor monotherapy.” PMID 39601743 ↗ Nov 2024 “P2Y12 inhibitor(Clopidogrel 75mg/day or Ticagrelor 180mg/day) for 9months after 3 months of DAPT(Aspirin 100mg/day + Clopidogrel 75mg/day or Aspirin 100mg/day + Ticagrelor 180mg/day)” NCT03447379 ↗ “dabigatran 110mg twice daily or 150mg twice daily+ aspirin 100mg once daily / clopidogrel 75mg once daily / ticagrelor 90mg twice daily / cilostazol 100mg twice daily” NCT06058130 ↗ “All subjects will be received 12 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.” NCT02402491 ↗ “The Investigator will decide whether to use ticagrelor first; if ticagrelor is not the first-line recommended drug, then clopidogrel will be considered.” NCT07587099 ↗ “Subjects must be treated with one of the following P2Y12 inhibitors (clopidogrel, prasugrel, or ticagrelor) for 3 months following the index procedure.” NCT02605447 ↗ “Aspirin 100 mg orally once daily + Clopidogrel 75 mg orally once daily, or Aspirin 100 mg + Ticagrelor 90 mg orally twice daily, continued for 21 days” NCT07476898 ↗ “Doses are aspirin either 81mg or loading dose 325mg, clopidogrel either 75mg or loading dose 300mg, ticagrelor either 90mg or loading dose 180mg.” NCT06943586 ↗ “Participants that are carriers of the CYP2C19 gene will receive either Ticagrelor monotherapy, or dual therapy with Ticagrelor and Aspirin.” NCT07602257 ↗ “Potent P2Y12 inhibitor-based SAPT (ticagrelor 90 mg bd, or prasugrel 5 or 10 mg od, at the discretion of the investigator) during 2 years.” NCT05650411 ↗ “Patients with a LOF-allel will receive ticagrelor (tablet of 90mg twice daily) or prasugrel (tablet of 10mg once daily) for 6 months.” NCT05773989 ↗ “DAPT - one of three (3) antiplatelet medications: ticagrelor (Brilinta), clopidogrel (Plavix) or prasugrel (Effient) with Aspirin.” NCT03606642 ↗ “A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders” NCT00642811 ↗ “Day 1(within 6.0 hours of onset, before or after intravenous thrombolysis) : Ticagrelor (180mg) + Aspirin (100mg), one dose;” NCT06316570 ↗ “High-risk patients with prior myocardial infarction will receive ticagrelor 60 mg twice daily wiht aspirin 100 mg daily” NCT05936606 ↗ “potent P2Y12 inhibitor monotherapy will be administered as prasugrel 10 mg once daily or ticagrelor 90 mg twice daily.” NCT07684742 ↗ “Including dabigatran 110 mg b.i.d. (Boehringer Ingelheim, Germany) plus ticagrelor 90 mg b.i.d. (AstraZeneca, Britain)” NCT03234114 ↗ “aspirin 100 mg daily plus clopidogrel 75 mg daily or ticagrelor 90 mg per dose, twice daily for 30 consecutive days” NCT07195812 ↗ “The other group discontinued antiplatelets (i.e. clopidogrel, ticagrelor, prasugrel) for 7 days before colonoscopy.” NCT02865824 ↗ “Prasugrel (10 mg/day) or Ticagrelor (180 mg/day) are strongly recommended as compared to Clopidogrel (75 mg/day)).” NCT02118870 ↗ “Subjects randomized to the Monotherapy Group will be treated with ticagrelor or prasugrel alone for 12 months.” NCT04360720 ↗ “Ticagrelor will be administered at a loading dose of 180 mg, followed by 90 mg twice daily maintenance dose.” NCT03005704 ↗ “(ASA 100mg daily + Ticagrelor 90mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.” NCT01955200 ↗ “Patients will be conventionally received ticagrelor 90mg bid or clopidogrel 75mg qd + aspirin 100 mg qd” NCT06283888 ↗ “All eligible STEMI patients will be received standard DAPT (ticagrelor or clopidogrel plus aspirin).” NCT06013020 ↗ “75 mg clopidogrel per day (or ticagrelor or cilostazol) for the initial 90 days after randomization” NCT07495969 ↗ “A loading dose of Ticagrelor 180mg followed by a dose of 90mg b.i.d. (during 48 hours)” NCT02698618 ↗ “aspirin (≤100mg per day), clopidogrel (75mg per day) or ticagrelor (90mg twice daily)” NCT05077683 ↗ “early escalation (low-dose ticagrelor at 60 mg twice daily plus aspirin <6 months)” PMID 40886179 ↗ May 2026 “receive either ticagrelor monotherapy (90 mg twice daily) after <1 month of DAPT” PMID 37878786 ↗ Oct 2023 “Aspirin 75-325 mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)” NCT04045665 ↗ “doses of clopidogrel (n = 94), prasugrel (n = 43) or ticagrelor, (n = 143).” PMID 34143384 ↗ Jun 2021 “Dual antiplatelet therapy (aspirin plus either clopidogrel or ticagrelor)” NCT05782270 ↗ “Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets” NCT01732822 ↗ “DAPT with acetylsalicylic acid + prasugrel or ticagrelor for 1 month.” NCT05952206 ↗ “Ticagrelor (loading dose of 300mg before maintenance dose of 90 mg/d)” NCT03533153 ↗ “Clopidogrel resistant patients were given ticagrelor 90mg bid.” NCT06269432 ↗ “aspirin100mg qd+ticagrelor60mg bid+warfarin(INR1.8-2.2)” NCT03415386 ↗ “Ticagrelor: administered enterally at 60mg twice daily” NCT02735707 ↗ “Free choice among clopidogrel, prasugrel or ticagrelor” NCT01477775 ↗ “* Month 0-1: Aspirin 100 mg qd + Ticagrelor 90 mg bid” NCT07432516 ↗ “Aspirin and ticagrelor 30 days after DES implantation” NCT06339021 ↗ “Ticagrelor (180 mg/day) or Clopidogrel (75 mg/day)” NCT03008083 ↗ “Ticagrelor is a new P2Y12 ADP receptor antagonist.” NCT01626534 ↗ “Ticagrelor was the preferred P2Y12 inhibitor.” PMID 37227729 ↗ May 2023 “for flow diversion, give ticagrelor 60mg bid.” NCT05825391 ↗ “50 patients treated with ticagrelor 60mg bid” NCT05903976 ↗ “DAPT with prasugrel (or ticagrelor) and ASA” NCT05262803 ↗ “aspirin, clopidogrel, ticagrelor” NCT04012541 ↗ “ticagrelor 180 mg” NCT04754789 ↗ “Drug: Ticagrelor” NCT02233790 ↗ “Ticagrelor” NCT01826175 ↗ |
| Known as | AR-C126532XX | ChEMBL registry synonym — accepted as the source's own label CHEMBL398435 ↗ |
| Known as | AZD6140 | “A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders” NCT00642811 ↗7“Ticagrelor (AZD6140) is a reversible, potent, oral adenosine diphosphate (ADP) P2Y12 receptor blocker” NCT03881943 ↗ |
| Known as | Brilavus | “the other one took ASA 80 mg once a day and ticagrelor 90 mg that is produced by Abidi company available in market as Brilavus twice a day” NCT05858918 ↗ |
| Known as | Brilinta | “Ticagrelor (Brilinta) 90 mg bd, 2 weeks; followed with Clopidogrel (Plavix) 75 mg qd, 2 weeks” NCT02459288 ↗5“Ticagrelor (Brilinta®) (AstraZeneca Pharmaceuticals, Wilmington, NC, USA).” PMID 23826440 ↗ Jun 2013 “Drug: ticagrelor (Brilinta) 90 mg tablets, 2 tablets chewed” NCT04567290 ↗ “A2: Ticagrelor (BRILINTA®, AstraZeneca S.A. de C.V.) A3:” NCT07444164 ↗ “Ticagrelor Oral Tablet [Brilinta]” NCT04946929 ↗ |
| Known as | BRILINTA (ticagrelor) | “"Brilinta"(Ticagrelor)” NCT02064985 ↗3“BRILINTA (ticagrelor)” NCT01589978 ↗ “Brilinta (ticagrelor)” NCT01823510 ↗ “Brilinta (ticagrelor” NCT01642238 ↗ |
| Known as | Brilique | “It consists in oral ingestion of 1.5g of paracetamol (Contents of 3 Doliprane® capsules 500 mg) and 60 mg prasugrel (6 tablets Efient ® 10 mg) or 180 mg ticagrelor ( 2 tablets...” NCT02251249 ↗3“Patiënt interventional treatment, with dabigatran + ticagrelor (Brilique) 90mg twice daily up to 12 months.” NCT04688723 ↗ “Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water” NCT02400333 ↗ “Drug: Ticagrelor (Brilique) 90” NCT03884530 ↗ |
| Known as | D578 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03671941 ↗ |
| Known as | Possia | ChEMBL registry synonym — accepted as the source's own label CHEMBL398435 ↗ |
| Known as | Ticag. | “A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders” NCT00642811 ↗ |
| Known as | Ticagrelor (Brilinta) | “Ticagrelor (Brilinta)” NCT03606642 ↗ |
| Known as | Ticagrelor (Brilique) | “Ticagrelor (Brilique)” NCT02224274 ↗ |
| Action | Inhibit | “Ticagrelor is an oral, reversible, direct-acting inhibitor” PMID 19717846 ↗ Aug 2009 |
| Modality | Small molecule | “cyclopentyl-triazolo-pyrimidine ticagrelor” PMID 24371012 ↗ Dec 2013 |
| Route | Oral | “Ticagrelor is an oral, reversible, direct-acting inhibitor” PMID 19717846 ↗ Aug 2009 |
| Target | P2RY12 | “ticagrelor, a reversibly binding P2Y(12) receptor antagonist” PMID 24861133 ↗ Aug 2014 |